ABSTRACT
There are 35 million people living with human immunodeciency virus (HIV) infection globally, according to the latest 2012 estimates (Joint United Nations Program on HIV/AIDS [UNAIDS]) [1]. Transnational and domestic initiatives on HIV prevention, diagnostics, and provision of antiretroviral drugs have rapidly expanded, yet signicant challenges remain in improving the effectiveness of these efforts. Although the number of individuals receiving antiretroviral therapy (ART) tripled in the last 5 years, 66% of individuals in middle-and low-income countries living with HIV and eligible for ART under the 2013 World Health Organization (WHO) treatment guidelines are not receiving treatment [1].
